Sociedad Americana de Hirudoterapia

Proteinase inhibitors from the medicinal leech Hirudo medicinalis

Research article published in Biochemistry. Biokhimiia (2001)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Farmacología salivalDesarrollo de fármacosBaskova I, Zavalova L · Biochemistry. Biokhimiia, 2001

Abstract

The medicinal leech Hirudo medicinalis produces various types of proteinase inhibitors: bdellins (inhibitors of trypsin, plasmin, and acrosin), hirustasin (inhibitor of tissue kallikrein, trypsin, alpha-chymotrypsin, and granulocyte cathepsin G), tryptase inhibitor, eglins (inhibitors of alpha-chymotrypsin, subtilisin, and chymasin and the granulocyte proteinases elastase and cathepsin G), inhibitor of factor Xa, hirudin (thrombin inhibitor), inhibitor of carboxypeptidase, and inhibitor of complement component C1s. This review summarizes data on their primary and tertiary structures, action mechanisms, and biological activities.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAntithrombin IIICarboxypeptidasesCarboxypeptidases AComplement Inactivator ProteinsHirudinsHumansInvertebrate HormonesLeechesOrganic ChemicalsProtease InhibitorsProteins

Resumen

The medicinal leech Hirudo medicinalis produces various types of proteinase inhibitors: bdellins (inhibitors of trypsin, plasmin, and acrosin), hirustasin (inhibitor of tissue kallikrein, trypsin, alpha-chymotrypsin, and granulocyte cathepsin G), tryptase inhibitor, eglins (inhibitors of alpha-chymotrypsin, subtilisin, and chymasin and the granu...

Por qué esto importa para la hirudoterapia

Advances understanding of leech salivary bioactive compounds and their therapeutic potential.

Citación

Proteinase inhibitors from the medicinal leech Hirudo medicinalis.

Baskova I, Zavalova L · Biochemistry. Biokhimiia, 2001

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Proteinase inhibitors from the medicinal leech Hirudo medicinalis | ASH